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Abstract
Background: SOX2, a high mobility group (HMG)-box containing transcription factor, is a key regulator during
development of the nervous system and a persistent marker of neural stem cells. Recent studies suggested a role
of SOX2 in tumor progression. In our previous work we detected SOX2 in glioma cells and glioblastoma
specimens. Herein, we aim to explore the role of SOX2 for glioma malignancy in particular its role in cell
proliferation and migration.
Methods: Retroviral shRNA-vectors were utilized to stably knockdown SOX2 in U343-MG and U373-MG cells. The
resulting phenotype was investigated by Western blot, migration/invasion assays, RhoA G-LISA, time lapse video
imaging, and orthotopic xenograft experiments.
Results: SOX2 depletion results in pleiotropic effects including attenuated cell proliferation caused by decreased
levels of cyclinD1. Also an increased TCF/LEF-signaling and concomitant decrease in Oct4 and Nestin expression
was noted. Furthermore, down-regulation of focal adhesion kinase (FAK) signaling and of downstream proteins
such as HEF1/NEDD9, matrix metalloproteinases pro-MMP-1 and -2 impaired invasive proteolysis-dependent
migration. Yet, cells with knockdown of SOX2 switched to a RhoA-dependent amoeboid-like migration mode
which could be blocked by the ROCK inhibitor Y27632 downstream of RhoA-signaling. Orthotopic xenograft
experiments revealed a higher tumorigenicity of U343-MG glioma cells transduced with shRNA targeting SOX2
which was characterized by increased dissemination of glioma cells.
Conclusion: Our findings suggest that SOX2 plays a role in the maintenance of a less differentiated glioma cell
phenotype. In addition, the results indicate a critical role of SOX2 in adhesion and migration of malignant gliomas.
Background
Despite multimodal treatment the prognosis for glio-
blastoma (GBM), the most common and most malig-
nant brain tumor remains poor, with the majority of
patients dying within 1 year after diagnosis [1]. Glioblas-
tomas, gliomas of WHO grade IV, diffusely spread into
the surrounding brain and the invading tumor cells
migrate along the white matter tracks and assemble
satellites around neuron cell bodies, blood vessels and
the subpial region [2,3]. Since glioblastoma cells infil-
t r a t ew i d ea r e a so ft h eb r a i ne v e r yr e s e c t i o no ft h eb u l k
tumor is usually followed by a tumor re-initiation at the
resection site or at another place in the brain [4,5]. The
cellular origin of glioblastoma is still under investigation
and it is hypothesized that this tumor arises from trans-
formed pluripotent precursor cells, so called glioblas-
toma initiating stem cells [6,7].
Recently, we reported expression of the stem cell mar-
ker SOX2 in glioblastoma specimens [8]. SOX2 is a 34
kDa HMG-box containing transcription factor belonging
to the sex determining region Y (SRY)-box proteins
which play an important role in development, in parti-
cular in the central nervous system [9-11]. It has been
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any medium, provided the original work is properly cited.reported, that SOX2 preserves the undifferentiated state
of neural progenitor cells in chicken [12] and is a persis-
tent marker of multipotent neural stem cells, both in
murine embryos and mice [13]. SOX2 positively controls
self-renewal of neural stem cells [14] and its ectopic
overexpression inhibits neural fate differentiation
[13,15,16]. Several lines of evidence suggest an onco-
genic role of SOX2 in tumor progression. Hence SOX2
expression was found to be a negative prognostic mar-
ker of esophageal squamous cell carcinoma [17], and
was correlated with later stages and invasive phenotype
of pancreatic carcinoma [18]. Furthermore, SOX2 has
been observed in 43% of basal breast carcinomas which
was associated with a less differentiated phenotype [19].
Contrary to these reports SOX2 overexpression and
concomitant Oct4 overexpression was found to be a
marker of less progressive squamous cell lung cancer
and hypopharyngeal squamous cell carcinoma, respec-
tively, and predicted a better clinical outcome [20,21].
The situation becomes even more complicated by a
recent report describing a tumor-suppressive function of
SOX2 in gastric cancers and gastric cancer cell lines
[22].
A recent study revealed robust SOX2 expression in
brain tumors of glial lineages expressing the astrocytic
marker protein glial fibrillary acidic protein (GFAP)
[23]. Other brain tumors, such as medulloblastomas and
pineoblastomas, displayed markers of neuronal differen-
tiation and lacked SOX2 expression [23]. It can be
assumed that SOX2 in gliomas might augment the
maintenance of a less differentiated astroglial phenotype
and positively influence proliferation of glioblastoma
cells in a similar manner as in glial progenitor cells.
Therefore, SOX2 might represent a suitable target for
RNAi to treat malignant gliomas. In line with this, it has
recently been reported that RNAi-mediated knockdown
of SOX2 in glioblastoma tumor initiating cells (TICs)
led to impaired proliferation [24]. However, the molecu-
lar mechanisms leading to this decreased cell growth
remain obscure. So far only a small number of investiga-
tions have touched the role of SOX2 in governing can-
cer cell proliferation and migration capacity on the
molecular level [25,26].
In the present study we sought to elucidate the role of
SOX2 in glioma malignancy. We also wanted to investi-
gate whether RNAi of SOX2 might be amendable to
treat malignant gliomas. For the investigations we used
SOX2-positive cell lines U343-MG and U373-MG,
which upon RNAi of SOX2 were still viable but showed
an attenuated S-phase entry associated with decreased
levels of phosphorylated RB protein and reduced levels
of cyclinD1. Notably, the cells lost expression of Oct4
and Nestin indicative for a shift from a stem cell-like
phenotype to a more differentiated cell type.
Furthermore, a loss of invasive proteolysis-dependent
migration capacity and a reduced matrix adhesion due
to a reorganized actin cytoskeleton were noted. These
changes were accompanied by an increased TCF/LEF-
and diminished FAK-signaling. Further analysis revealed
that the loss of invasive proteolysis-dependent migration
capacity of glioma cells with knockdown of SOX2 could
b ec o m p e n s a t e db yas h i f tt oa m o e b o i dm i g r a t i o ng o v -
erned by increased RhoA/ROCK2 signaling. In line with
this, xenograft experiments revealed an increased disse-
mination of U343-MG cells transduced with shRNA tar-
geting SOX2 in mouse brain which was associated with
a decreased survival of mice. Our study is the first that
describes the impact of SOX2-RNAi on the cell cycle
and on the migratory behavior of glioma cells on the
molecular and cellular level. In particular, a potential
development of an amoeboid phenotype after SOX2-
RNAi might be dangerous when SOX2 or downstream
molecules are targeted in cancer therapies.
Results
SOX2-RNAi induces morphological changes in U343-MG
and U373-MG cells and an attenuated cell growth
U343-MG and U373-MG cells were tranduced using
retroviral vectors encoding for EGFP and for small hair-
pins 788 or 2378 (shSOX2 #788 or shSOX2 #2378),
respectively, targeting SOX2 mRNA. As control a retro-
viral vector encoding a shRNA targeting luciferase was
included. Both SOX2-shRNAs efficiently blocked SOX2
protein expression when tested in Western blot analysis
and indirect immunofluorescence analysis using an anti-
body specific for SOX2 and when compared to the
appropriate control cells (Figure 1a, b).
The shRNA-treated cells showed strong EGFP expres-
sion, marking successful gene transfer, within two days
after transduction (see additional file 1). Starting with
day 4 after transduction significant fractions of glioma
cells expressing shSOX2 #788 and #2378 started to
develop membrane alterations, reminiscent of apoptotic
blebs (Figure 2a, b). Furthermore, these cells tend to
lose adherence from the cell culture dish. Phalloidin-
TRITC-staining of the actin filaments of cells with
knockdown of SOX2 frequently revealed a reorganized
actin cytoskeleton displaying a significantly thickened
cortical actin network with emerging membrane protru-
sions containing actin filaments (Figure 2c, d).
Despite the appearance of these apoptosis-like mem-
brane alterations no increases in the fraction of apopto-
tic cells having hypodiploid (SubG1) genomes were
noted (Figure 3a). Instead, knockdown of SOX2 in
U343-MG and U373-MG resulted in significant
increases in the fraction of cells in G1-phase when com-
pared to shLuc-transduced control cells (Figure 3a).
Thus, knockdown of SOX2 obviously impaired the G1
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MG and U373-MG cells with knockdown of SOX2
showed a decrease in cell growth when compared to the
shLuc-treated controls (Figure 3b). However, it cannot
completely be ruled out that this effect in part was due
to the loss of detached cells with knockdown of SOX2
during standard cell cultivation. Next, the molecular
mechanism underlying the diminished S-phase entry
induced by loss of SOX2 function was examined. Wes-
tern blot analysis five days after transduction revealed
an impaired expression of cyclinD1 in U343-MG and
U373-MG glioma cells with knockdown of SOX2 when
compared to cells transduced with the shLuc control
vector, whereas cyclinE levels remained unaffected (Fig-
ure 3c). Interestingly, a reduced level of retinoblastoma
protein (RB protein) phosphorylated at threonine 356,
one of the phosphorylation sites of the cyclinD1-Cdk4
complex, was noted (Figure 3c). On the other hand, a
cell cycle arrest in G1 upon SOX2-RNAi through induc-
tion of cell cycle inhibitor p21
waf/cip was not detectable
in the U343-MG cell line which is known to have func-
tional p53 [27] and also no p21
waf/cip induction was
observed in total protein lysates of U373-MG cells
which have mutant p53 [28] (Figure 3d). Testing apop-
tosis by investigating the appearance of cleaved pro-
caspase 3 in Western blot analyses showed no induction
of apoptosis (Figure 3d). In addition, a clonogenic assay
revealed only a moderate decrease in long term survival
of cells with knockdown of SOX2 when compared to
shLuc-control cells (see additional file 1). Thus, the pre-
vailing effect of the SOX2 knockdown was an attenuated
cell cycle progression which was accompanied by a
notable change in cell adherence and cell morphology.
SOX2 knockdown results in increased TCF/LEF-1-signaling
and a decrease in expression of stem cell markers Oct4
and Nestin
Next we were interested whether knockdown of SOX2
affects the differentiation status of the glioma cells
besides the attenuated S-phase entry. Recent studies
have demonstrated involvement of SOX2 in the wnt/b-
Catenin-mediated regulation of Transcription factor T
cell specific/Lymphoid enhancer binding factor (TCF/
LEF) transcription factors. In particular, it has been
shown, that SOX2 inhibits canonical wnt-signaling in
vertebrates leading to decreased TCF/LEF-mediated
transcriptional activity which concomitantly inhibited
cellular differentiation processes [29]. When we investi-
gated the b-Catenin/TCF/LEF transcriptional activity by
using a firefly luciferase reporter gene assay we revealed
a 3-fold and 4-fold higher TCF/LEF signaling in U343-
MG and U373-MG cells with knockdown of SOX2
when compared to controls (Figure 4a, b). In parallel,
Western blot and indirect immunofluorescence analyses
demonstrated a decrease in the steady state expression
levels of stem cell transcription factor Oct4 (Figure 4c,
d). Also a decrease in Nestin expression was noted in
U343-MG and U373-MG cells with knockdown of
SOX2 whereas expression levels of the astrocytic marker
GFAP and of b-catenin remained unchanged (Figure
4c). Our data suggest that SOX2 expression preserves
stem cell characteristics and on the other hand can
modulate the proliferation of U343-MG and U373-MG
glioma cells.
SOX2-RNAi decreases invasive proteolysis-dependent
migration of glioma cells
Because we observed remarkable morphological changes
and a remodeling of the actin cytoskeleton of the glioma
cells with knockdown of SOX2 we hypothesized that the
migratory capacity of these cells might be affected. We
therefore employed transwell migration assays to exam-
ine the invasive proteolysis-dependent migration capa-
city of U343-MG and U373-MG glioma cells through a
membrane-bound collagen matrix. Interestingly, the
proteolysis-dependent invasion potential of SOX2
depleted cells was significantly reduced compared to
control cells (Figure 5a). The shSOX2-U373-MG cells
had an invasion index of 25.7% (+/- 0.9%) compared to
Figure 1 Efficient transduction and stable knockdown of SOX2
in glioblastoma cell lines U343-MG and U373-MG. a: Western
blot analysis showing knockdown of SOX2 in transduced U343-MG
and U373-MG cells using pRVH-N1-EGFP vectors encoding the small
hairpins sh788 and sh2378. As control, total protein lysates of cells
transduced with shLuc are included. The membrane was stripped
and probed for tubulin in order to confirm equal protein loading. b:
Indirect immunofluorescence analysis of SOX2 expression in U343-
MG and U373-MG cells after transduction of retroviral vectors
encoding shRNA-shSOX2-788 and shRNA-SOX2-2378. Note the loss
of SOX2-immunosignals in transduced EGFP-positive cells. Controls
transduced with shLuc are included.
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effect was even stronger for U343-MG cells. Here, the
invasion index was reduced from 76.5% (+/- 7.83%) for
shLuc controls to 4.1% (+/- 0.22%) measured for the
shSOX2-U343-MG cells. Thus, knockdown of SOX2
expression impaired proteolytic invasion of U343-MG
and U373-MG glioma cells through collagen matrices.
To elucidate, in which way the migratory behavior was
compromised in the SOX2-knockdown cells, we focused
on focal adhesion kinase (FAK), on its downstream sig-
naling protein human enhancer of filamentation (HEF1/
NEDD9) and metallo-matrixproteases which are essen-
tial for a proteolysis-dependent invasion and migration
of glioma cells [30,31]. Initial step for FAK signaling is
an autophosphorylation at Y397, which occurs after
binding of integrins to the ECM. This autophosphoryla-
tion of FAK has been reported to promote the binding
and activation of the proto-oncogenic cytosolic tyrosine
kinase c-Src [32]. c-Src subsequently phosphorylates
Crk-associated substrates (CAS) proteins, such as HEF1/
NEDD9 [31]. Phosphorylated CAS proteins promote the
activation of small GTPases such as cdc42 and Rac1
which affects membrane protrusion and migration [30].
Interestingly, Western blot analyses at two different
time points 3 and 5 days after transduction revealed a
marked reduction of FAK phosphorylation at Y397 for
the SOX2-depleted glioma cells when compared to
shLuc-transduced controls (Figure 5b). Moreover, our
analyses revealed a downregulation of HEF1/NEDD9
and of metallo-matrixproteases pro-MMP1 and pro-
Figure 2 Development of non-apoptotic membrane protrusions in SOX2-silenced U343-MG and U373-MG cells. a: Representative
microscopy images showing U343-MG cells with knockdown of SOX2 and control cells transduced with shLuc. b: Quantification of the fraction
of cells showing membrane blebs after knockdown of SOX2. Bars indicate standard deviation. c: Confocal laser scan micrsocopy images showing
Phalloidin-TRITC staining of actin filaments in U343-MG and U373-MG cells after knockdown of SOX2. CU: Close ups on cortical actin filaments.
As control shLuc transduced U343-MG and U373-MG cells are included. Note the increased thickness of cortical actin filaments (arrowheads) and
the development of membrane alterations in cells with knockdown of SOX2. d:. Analysis of the thickness of cortical actin filaments: The thickness
of the cortical actin network is increased in cells with knockdown of SOX2 when compared to U343-MG and U373-MG shLuc control cells. * p <
0.05; **p > 0.01 when SOX2-silenced cell were compared to shLuc controls.
Oppel et al. Molecular Cancer 2011, 10:137
http://www.molecular-cancer.com/content/10/1/137
Page 4 of 16MMP2 in SOX2-depleted U343-MG and U373-MG
glioblastoma cells (Figure 5c). Thus, knockdown of
SOX2 decreases expression levels for proteins involved
in invasive proteolysis-dependent migration.
Glioma cells with knockdown of SOX2 acquire an
amoeboid-like phenotype by increased RhoA/ROCK2-
signaling
When we tested migration through uncoated mem-
branes we noted a significant higher number of U343-
MG and U373-MG glioma cells with knockdown of
SOX2 in the bottom well of the Boyden-chamber bear-
ing a rounded cell morphology and having membrane
protrusions when compared to cells transduced with the
shLuc control vector. We hypothesized that these cells
compensate the loss of invasive proteolysis-dependent
migration by acquiring an amoeboid-like migration.
This kind of cell motility has been described to use a
path-finding instead of a path generating migration
strategy [33]. We calculated that the shSOX2-U343-
MG cells had an amoeboid migration index of 9.47%
(+/- 2.77%) compared to 1.67% (+/- 0.34%) measured
Figure 3 Effects of SOX2-RNAi on cell proliferation, cell cycle and induction of apopotosis in U343-MG and U373-MG glioma cells. a:
Propidium iodide-staining and cell cycle analysis of U343-MG and of U373-MG cells 5 days after transduction with shRNA vectors revealed no
induction of apoptosis (SubG1 fraction) but a decrease of cell fractions in S/G2/M-phases. As controls, shLuc transduced cells were included. As
positive control for apoptosis U343-MG and U373-MG wild type cells were treated with doxorubicin to induce apoptosis (Wt+Dox). b: Growth
kinetics of U343-MG and U373-MG cells transduced with shSOX2 #788, shSOX2 #2378, and shLuc (control). Note the gradual decrease in cell
numbers in glioma cells with knockdown of SOX2. Bars in a: and b: indicate standard deviation. * p < 0.05 when SOX2-silenced cell were
compared to shLuc controls. c: Western blot analysis of SOX2 and of cell cycle regulator proteins cyclinD1, cyclinE, retinoblastoma protein (pRB)
and of pRB-pT
356, indicating phosphorylation by the cyclinD1-cdk4 complex. Note the decreases in cyclinD1 expression and the concomitant
diminished levels of pRB-pT
356 in cells with knockdown of SOX2. d: Western blot analysis showing no cleavage of pro-caspase 3 and no increase
of p21
waf/cip inhibitor of cyclin-dependent kinases Cdk4/6 in U343-MG and U373-MG cells transduced with shSOX2 #2378 and in controls
transduced with shLuc. (+) depicts U343-MG cells treated with doxorubicin serving as positive control for induction of apoptosis and induction
of p21
waf/cip. Equal loading of lanes in c: and d: was verified using tubulin antibody.
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migration index for U373 was 14.3% (+/- 0.5%) and for
shLuc controls 4.03% (+/- 0.97%) (Figure 6b).
Life cell imaging was employed in order to examine
the biology of the observed morphological changes in
SOX2-depleted glioma cells. For the analysis we used
U343 glioma cells which developed membrane protru-
sions accompanied by contractions of the cell body 5
days after transduction of the vector encoding shSOX2
#2378 and EGFP (Figure 6c). The cells further con-
tracted and then developed larger protrusions until a
fully rounded morphology was reached (Figure 6d, and
additional file 2). Interestingly, fully rounded cells
started to stretch and performed worm-like movements
(Figure 6e, additional files 3, and 4). All analyzed shLuc
control cells so far did not exhibit such remarkable
alterations in cell morphology.
To further corroborate a possible association of the
SOX2 RNAi-induced phenotype to the proteolysis-
independent amoeboid migration mode we focused on
the marker proteins CD44 and ezrin. Amoeboid migrat-
ing cells display an ezrin pole at the site of the mem-
brane which faces the direction of movement [34-36].
The cytoskeletal protein ezrin connects actin filaments
to the plasma membrane protein CD44 [37] and thereby
links the mechanical force of the cytoskeleton to extra-
cellular matrices (ECM) containing hyaluronic acid, a
described ligand for CD44 [38]. In order to identify the
isoforms of CD44 we performed Western blot analysis
and identified the standard CD44 isoform (CD44s) in
U343-MG and U373-MG cells (see additional file 5).
Then we used confocal laser scan microscopy to investi-
gate in detail the intracellular localization of CD44 and
ezrin. In shLuc-U343-MG control cells ezrin and CD44
were concentrated around the cell body in long fiber-
like protrusions (Figure 7a, b). In shLuc-U373-MG cells
both proteins were seen in similar structures connecting
the cell to the ground of the culture dish (Figure 7e, f).
In contrast, in U343-MG and U373-MG cells with
knockdown of SOX2 both proteins were found to be
reorganized and were concentrated at a distinct pole
emerging from the cell body (Figure 7c, d and 7g, h).
Additional double immunofluorescence analyses using
cells transduced with retroviral vectors in which the
EGFP was substituted for a puromycin resistance cas-
sette confirmed colocalization of CD44 and ezrin in the
protrusions (see additional file 5).
In order to further prove the development of the amoe-
boid-like phenotype we focused on the RhoA/ROCK-
pathway which is essential for amoeboid migration
[34,39]. We did not detect ROCK1 protein (data not
shown) whereas ROCK2 and RhoA were expressed in
U343-MG and U373-MG cells (Figure 8a, c). In its
active GTP-bound form, the GTPase RhoA activates
ROCK2 which regulate contractile actin/myosin II ele-
ments [39].
AR h o AG - L I S Aw a su s e dt od e t e r m i n et h el e v e l so f
R h o A - G T P .T oi n v e s t i g a t eR h o Ar e g u l a t i o ni nU 3 4 3 -
MG and U373-MG wild type cells, protein lysates of
serum-starved cells and of cells subsequently treated
with lysophosphatic acid (LPA), a common activator of
RhoA, were included in the experiments. The analysis of
these controls confirmed an intact RhoA regulation of
U343-MG and U373-MG wild type cells (data not
shown). When testing U343-MG and U373-MG cells
with knockdown of SOX2, a significant increase of
RhoA-GTP was observed when compared to the shLuc
controls (Figure 8a). Hence, RNAi of SOX2 induces an
increased RhoA signaling in U343-MG and U373-MG
glioma cells.
Since increased RhoA-activation should lead to ROCK
activation we sought to confirm the RhoA/ROCK activa-
tion on a functional level. We therefore utilized the
Figure 4 SOX2-RNAi increases TCF/LEF-signaling and decreases
Nestin and OCT4 steady state protein expression levels. a:
U343-MG and b: U373-MG glioma cells stably expressing TCF/LEF-
driven luciferase were transduced with sh2378 or empty vector and
analyzed. Note the increase in luciferase activity after knockdown of
SOX2 in both glioma cell lines. Bars indicate standard deviation. * p
< 0.05 when SOX2-silenced cell were compared to controls. c:
Western blot analysis for stem cell markers Nestin and Oct4 in
U343-MG and U373-MG cells with knockdown of SOX2 showing
loss of protein expression when compared to shLuc controls. Steady
state protein expression levels of astrocyte marker glial fibrillary
acidic protein (GFAP) and b-Catenin remained unchanged. Equal
loading of lanes was confirmed using tubulin antibodies. d: Indirect
immunofluorescence showing decrease of Oct4 immunosignals in
U343-MG and U373-MG cells treated with sh2378 when compared
to shLuc controls. Magnification bars: 20 μm.
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bit ROCK proteins [40] and monitored its effects on
SOX2-depleted U343-MG and U373-MG glioma cells
using life cell imaging. As anticipated the dynamic
membrane alterations of SOX2-depleted cells were abol-
ished in both cell lines within a few minutes (Figure 8b,
and see additional file 6). To further corroborate that
ROCK2 was inactivated by Y27632 we analyzed the acti-
vation status of the myosin light chain (MLC). Phos-
phorylation of MLC (MLC-P) of myosin II at serine 19
induces its interaction with actin, which thereby acti-
vates myosin ATPase resulting in enhanced cell contrac-
tility [41]. It has been reported that besides the Ca
2
+-dependent myosin light chain kinase (MLCK) also
ROCK kinases phosphorylate MLC at serine 19 [41]. In
fact, we revealed that treatment with the ROCK inhibi-
tor Y27632 led to a decrease in MLC-P levels (Figure
8c) which indicates that ROCK2 is involved in the
development of the membrane protrusions occurring in
the U343-MG and U373-MG glioma cells with knock-
down of SOX2.
To verify that SOX2-depleted cells were motile, we
employed an organotypic brain slice migration assay.
Fresh quarters of mouse brains soaked with medium
containing FCS were incubated with serum starved
shLuc-U373-MG and shSOX2-2378-U373-MG cells,
respectively. After 36 hours the shSOX2-transduced and
the control cells had both invaded into the mouse brain
tissue. Due to the experimental setting, it was not possi-
ble to precisely quantify, whether cells with knockdown
of SOX2 or shLuc control cells have an improved
migration. However, it became clear that the glioma
cells with knockdown of SOX2 had the capacity to
migrate into the brain tissue (see additional file 7).
Knockdown of SOX2 increases spreading of orthopically
transplanted U343-MG glioma cells and decreases
survival of mice
In order to test the tumor initiation ability and the
migratory phenotype of U343-MG cells with knockdown
of SOX2 in vivo we stereotactically transplanted 5 × 10
5
glioma cells 5 days after transduction of shSOX2 #2378-
Figure 5 SOX2-RNAi affects adhesion, invasion and migration of glioma cells. a: Trans-well assay measuring the invasion of U343-MG- and
U373-MG glioma cells with stable knockdown of SOX2 and of shLuc control cells using extra cellular matrix (ECM)-coated Boyden chambers. The
calculation of the proteolysis-dependent invasion index was performed as described in the material and methods section. Bars indicate standard
deviation. * p < 0.01 when cells with knockdown of SOX2 were compared to shLuc controls. b: Western blot analysis of focal adhesion kinase
(FAK) and its activated phosphorylated form (FAK-pY
397). FAK and FAK-pY
397 was analyzed in SOX2 silenced (shSOX2-2378) and in control cells
(shLuc) at two different time points 3 days (3 d) and 5 days (5 d) after transduction. Note the decrease in FAK-pY
397 in cells with knockdown of
SOX2. c: Western blot analysis showing diminished expression of the human enhancer of filamentation protein (HEF1/NEDD9), and of pro-matrix
metalloproteinases (pro-MMPs) 1 and 2, in U343-MG and U373-MG glioma cells with knockdown of SOX2.
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cally injected into the right hemisphere the U343-MG
gliomas mostly grew along the surface of the brain. That
this phenomenon was due to technical difficulties was
excluded by parallel stereotactical injections of U87-MG
cells, which were found to grow exclusively intra-par-
enchymal at the site of injection (data not shown). We
conclude that the U343-MG cells exhibit a distinct
growth pattern when compared to standard cell lines
used for orthotopic xenografts such as U87-MG or
U251-MG. Yet, we observed a significant reduced survi-
val of mice transplanted with U343-MG cells transduced
with shSOX2 #2378 when compared to controls (Figure
9a). In line with the survival data the U343-MG tumors
with knockdown of SOX2 were larger. These tumors
Figure 6 SOX2-RNAi induces morphological changes in glioma
cells. Trans well assay using membranes lacking the ECM for
determination of proteolysis-independent amoeboid-like migration
of a: U343-MG and b: U373-MG cells with knock down of SOX2.
The calculation of the amoeboid-like migration index was
performed as described in the material and methods section. Bars
indicate standard deviation. * p < 0.05; ** p < 0.01 when cells with
knockdown of SOX2 were compared to shLuc controls. c-e: U343-
MG cell transduced with shSOX2 #2378 and expressing the marker
EGFP were monitored by life cell imaging. c: An adherent cell with
normal cell morphology develops protrusions of the membrane
which appear as little blebs. d: An intensive blebbing cell develops
less frequent, but larger blebs, and acquire a round cell
morphology; e: A fully rounded cell contracts the cell body and
migrates. Magnification bars: 30 μm.
Figure 7 U343-MG and U373-MG cells with knockdown of
SOX2 develop a single membrane protrusion containing ezrin
and CD44. U343-MG and U343-MG glioma cells were transduced
with retroviral vectors encoding EGFP and the indicated shRNA. Five
days after transduction cells were fixed and stained with primary
ezrin, CD44 antibodies and secondary Cy3-coupled antibodies as
depicted in the images. DNA counterstaining was performed using
Hoechst 33342. a, b: U343-MG cells transduced with shLuc control
vector. c, d: U343-MG cells transduced with shSOX2 #sh2378. e, f:
U373-MG cells transduced with shLuc control vector. g, h: U373-MG
cells transduced with shSOX2 #sh2378. Note in c: and g: the
development of a single cell protrusion containing ezrin and as
shown in d and h the appearance of CD44 in single protrusions in
cells with knockdown of SOX2. Magnification bars, in a, b, e, f: 20
μm; in c, d, g, h: 10 μm.
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ing blood vessels but also significantly augmented dif-
fuse infiltration into the brain parenchyma when
compared to shLuc-transduced controls (Figure 9b, c)
indicating an increased migratory capacity in the brain.
Discussion
SOX2 is involved in regulation of proliferation and
differentiation status of U343-MG and U373-MG glioma
cells
In our previous study we detected the stem cell marker
and transcription factor SOX2 in glioblastoma tissue
and glioblastoma cell lines [8] and hypothesized that it
might represent an ideal target for an experimental
RNAi approach for treatment of malignant gliomas. In
fact, we found that RNAi of SOX2 attenuated prolifera-
tion of U343-MG and U373-MG glioma cells. Yet, cells
with knockdown of SOX2 remained viable for weeks in
cell culture, an observation which also has been
reported by Gangemi et al. for glioblastoma tumor-initi-
ating cells (TICs) with knockdown of SOX2 [24]. On
the other hand, the same study revealed that the knock-
down of SOX2 in glioblastoma TICs led to a moderate
but sustained decrease in cell proliferation which was
associated by a loss of Ki67 proliferation marker expres-
sion. Yet, the molecular mechanisms underlying the
observed growth inhibition remained elusive and it was
hypothesized that the loss of proliferative capacity was
linked to some kind of differentiation of the glioblas-
toma TICs. In our study, we show for the first time that
SOX2 knockdown led to an attenuated S-phase entry in
malignant glioma cells which was caused by diminished
levels of cyclinD1 and a concomitant decrease in the
amount of phosphorylated RB protein. Recently, the
same effect after SOX2 knockdown has been reported in
MCF7 breast carcinoma cells. Here, a decrease in prolif-
eration of MCF7 cells after SOX2-RNAi was demon-
strated to be due to diminished cyclinD1 expression
Figure 8 SOX2-RNAi-induced membrane protrusions are associated with increased RhoA activity and are repressed by blocking ROCK.
a: RhoA-G-Lisa of U343-MG and U373-MG cells with knockdown of SOX2 compared to shLuc control cells. Protein lysates were prepared and
subjected to RhoA-G-LISA. Inlays: RhoA-input in G-LISA. *p < 0.05 when cells with knockdown of SOX2 were compared to the shLuc controls. b:
Inhibition of ROCK signaling downstream of RhoA with the small chemical compound Y27632 completely abolish membrane blebbing in U343-
MG with knockdown of SOX2. The inhibitor was added at time 00.00.00 (hh:mm:ss). c: Western blot analysis confirms ROCK2 expression in U343-
MG and U373-MG cells with knock down of SOX2 which is not affected by treatment with Y27632. The inhibition of ROCK led to diminished
levels of phosphorylated myosin light chain (MLC-P). Equal loading of the filters was confirmed by stripping the filters and probing with tubulin
antibodies. Densitometric analyses of Western blot signals normalized to tubulin signals are depicted.
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to facilitate the G1 to S1 transition. Noteworthy, the
same study revealed that the cyclinD1 promoter region
contains a functional SOX2 canonical binding site [26].
Hence, we suggest that RNAi of SOX2 in U343-MG and
U373-MG glioma cells impairs cyclinD1 transcription
and affects proliferation in the same way.
Interestingly, upon knockdown of SOX2 the expres-
sion of the stem cell markers Nestin and Oct4 was
decreased in U343-MG and U373-MG glioma cells sup-
porting the view that SOX2 preserves a more undiffer-
entiated cell phenotype as previously observed in neural
stem cells [12]. In parallel, an increased TCF/LEF-signal-
ing was noted. These results suggest that SOX2 and
TCF/LEF-signaling balances stem cell-like characteristics
and differentiation in U343-MG and U373-MG glioma
cells. So far we do not know the molecular mechanism
how loss of SOX2 affects TCF/LEF-signaling. Yet, a
recent report demonstrated that SOX2 maintains self
renewal of murine tumor-initiating osteosarcoma cells
which were driven into osteogenic differentiation
through increased basal TCF/LEF-signaling after knock-
down of SOX2 and lost proliferative capacity [29]. Inter-
estingly, the same study showed that an increase in wnt-
mediated TCF/LEF-signaling led to a decrease in endo-
genous SOX2 expression. We suggest that SOX2 expres-
sion in U343-MG and U343-MG glioma cells might
inhibit TCF/LEF-signaling in the same way keeping the
Figure 9 U343-MG xenografts with knockdown of SOX2 are tumorigenic and show a increased spreading in the mouse brain. a:
Kaplan-Meier curves showing the survival of mice transplanted with 5 × 10
5 U343-MG cells with knock down of SOX2 and transduced with
shLuc, respectively. Two independent experiments are depicted, which show a significantly reduced survival of mice transplanted with SOX2
depleted U343-MG cells. Number of animals for each experiment and p values for logRank-test are depicted. b: Semi-quantitative analysis of
tumor size and specific traits of tumor spreading in the brain. Glioma cells with knockdown of SOX2 shows strong increased infiltration following
vessels and diffuse infiltration into the normal brain parenchyma. Bars indicate standard deviation. The p values for student’s t-Test are shown. c:
Representative images of U343-MG gliomas in mouse brain. A-C: U343-MG tumors transduced with shLuc; D-I: U343-MG tumors transduced
with shSOX #2378: A: Small superficially growing shLuc tumor (arrow heads) despite an intracerebral tumor cell reservoir (asterisk). B, C:
Magnifications of the tumor area shows a compact growth pattern with clearly visible tumor borders and minimal single cell infiltration
(arrowheads). D: U343-MG tumors with knockdown of SOX2 showing multilocular intracerebral growth (asterisks). E: Magnification of the tumor
area showing two distinct tumor populations with spindle cell morphology and smaller rounded nuclei (#). Asterisks mark an area with intense
single cell infiltration. F: Further magnification of the same area reveals tumor cells with spindle cell morphology growing along performed
perivascular spaces (arrowheads). G: U343-MG cells with knock down of SOX2 growing at perivacsular spaces (arrowheads). H: Necrosis in U343-
MG tumor with knockdown of SOX2 (asterisk). I: Area of U343-MG tumor with knockdown of SOX2 with small rounded nuclear morphology and
glomeruloid vascular endothelium proliferation (arrowheads). Magnification bars for A and D: 160 μm; B and E: 80 μm; C, F, G, and I: 40 μm. n.d.:
not detected.
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state. Although not proven so far, it also appears concei-
vable that the observed loss of intercellular adherence
and loss of focal adhesion after RNAi of SOX2 in U343-
MG and U373-MG glioma cells directly affects TCF/
LEF-signaling through elevated levels of cytosolic b-
Catenin.
However, the question whether increased TCF/LEF-
signaling might affect the migratory capacity of the
U343-MG and U373-MG glioma cells and therefore
potentially increases tumorigenicity (described in the
following paragraph) remains to be investigated.
SOX2 RNAi impairs proteolysis-dependent invasion and
induces an amoeboid-like phenotype
To our knowledge the migratory capacity of SOX2
silenced malignant glioma cells has not been investi-
gated so far. We report for the first time, that knock-
down of SOX2 impairs the invasive proteolysis-
dependent migration of glioma cells. Furthermore, we
demonstrated that loss of invasive proteolysis-dependent
migration of U343-MG and U373-MG cells was asso-
ciated with decreased FAK-signaling and diminished
HEF1/NEDD9 protein levels. Also, the expression levels
of pro-MMP1 and pro-MMP2, which have been
reported to be regulated by Ets-1 (v-ets erythroblastosis
virus oncogene homolog 1) transcription factor [42,43]
downstream of SOX2 [44,45] were diminished after
SOX2-RNAi.
Remarkably, U343-MG and U373-MG glioma cells
with knockdown of SOX2 were able to compensate the
loss of invasive proteolysis-dependent migration capacity
by acquiring an amoeboid-like migration modus [46].
To our knowledge, only mesenchymal migration has
been reported for glioma cells so far [47]. The shift to
the amoeboid-like migration mode was accompanied by
a reorganization of the cytoskeleton. We identified a
loss of actin stress fibers and the development of a pro-
nounced cortical actin network with concomitant forma-
tion of a cell pole containing ezrin and CD44. CD44 has
been described to link the actin cytoskeleton via ezrin to
hyaluronic acid (HA) [48,49]. HA is the principal glyco-
saminglycan found in the extracellular matrix (ECM) of
the brain and is distributed in white matter fiber tracts,
which is proposed to be the most frequent route of
glioma dissemination [50].
In line with previous reports describing amoeboid
migration, we detected an increased RhoA/ROCK2 sig-
naling in U343-MG and U373-MG cells with knock-
down of SOX2 [33,34]. That RhoA/ROCK2 signaling
was essential for this kind of migration was verified by
blocking ROCK2 downstream of RhoA by using the
inhibitor Y27632, which completely abolished the devel-
opment of an amoeboid-like phenotype.
So far we have not investigated the molecular
mechanisms linking SOX2 and RhoA/ROCK2. However,
a recent report indicates a role of cyclinD1 in inhibiting
RhoA/ROCK expression and signaling in mouse
embryonic fibroblasts whereas a cyclinD1 knock out
increased RhoA/ROCK-signaling [51]. Since we
observed that SOX2 depletion led to a decrease in
cyclinD1 expression we suggest that the same mechan-
ism might be involved in the increased RhoA/ROCK2
signaling in U343-MG and U373-MG glioma cells.
That the acquired amoeboid-like migration mode was
functional could be demonstrated by transwell assays
using membranes lacking ECM. Furthermore, the
SOX2-depleted cells were able to invade into mouse
brain tissue often showing a typical morphology bearing
membrane blebs. Strikingly, when we tested U343-MG
glioma cells with knockdown of SOX2 in orthotopic
xenografts we observed a significant decreased survival
of these mice when compared to controls. Furthermore,
histological analysis of the tumors demonstrated that
significantly more SOX2-depleted U343-MG cells spread
along vessels or diffusely spread into the normal brain
tissue. Our results contradict the study from Gangemi
et al. which demonstrates that RNAi of SOX2 reduces
the tumorigenicity of glioblastoma tumor-initiating cells
[24]. Our study furthermore contradicts reports which
show that ectopic overexpression of SOX2 enhances
tumorigenicity of prostate cancer cells [52] and of breast
cancer cells [53] but is in line with reports indicating a
tumor-suppressive function of SOX2 in gastric cancer
cells lines [22,54]. So far we cannot resolve the observed
discrepancies and it remained to be clarified whether
the genetic background of the cells, differentially
expressed molecular partners of SOX2 (i.e. Oct3,
Nanog), the long term adaptation of U343-MG and
U373-MG in cell culture or technical differences
account for the observed effects following RNAi of
SOX2. Nonetheless, in our study we demonstrate for
the first time a role of SOX2 in migration of glioma
cells. Noteworthy, in our experiments we showed that
SOX2 seems not to be fundamental for the maintenance
of U343-MG and U373-MG glioma cell proliferation.
Conclusions
In summary, we have confirmed SOX2 as important fac-
tor involved in the preservation of a less differentiated
glioma cell phenotype. Yet, our studies revealed that
SOX2 regulates cell-matrix interaction and invasive pro-
teolysis-dependent invasion of U343-MG and U373-MG
cells. Although long term GBM cell lines have their lim-
itations since they might differ in some aspects from
primary tumor cells, caution is advised when setting up
treatment strategies targeting SOX2 in glioblastoma
patients, since a decrease in invasion proteolysis-
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compensated by a switch to an amoeboid-like migration
which might affect survival of patients. Further investi-
gations using the SOX2-depleted glioblastoma cells and
primary GBM cell preparations, respectively, are war-
ranted which should give further insights of the role of
SOX2 in glioma cell biology.
Methods
Cell culture methods
U373-MG is a glioblastoma/astrocytoma derived cell
line; U343-MG is a glioblastoma-derived cell line. The
glioma cells were cultured on poly-L-lysine coated plas-
tic ware and in Basal Minimal Eagle medium (BME,
Invitrogen, Eggenstein, Germany) supplemented with 2
mM L-glutamine and 1% non-essential amino acids
(Biochrom, Berlin, Germany). 293T are human embryo-
nic kidney cells. They were cultured in Dulbecco’s mod-
ified Eagle medium containing 4.5 g/l glucose (PAA
Laboratories, Pasching, Austria). The medium was sup-
plemented with 10% heat inactivated fetal calf serum,
100 U/ml penicillin and 100 μg/ml streptomycin (both
Invitrogen). The proliferation of transduced glioma cells
was determined by counting total cell numbers using a
Neubauer microscope counting chamber. In brief, 10
5
cells were plated in triplicates at day 0 in 6 well culture
plates and viable cells were counted after 3, 5 and 7
days. Long term survival of transduced glioma cells was
tested by plating 1000 cells/dish. After three weeks
U 3 4 3 - M Ga n dU 3 7 3 - M Gc e l l sw e r es t a i n e dw i t h
Giemsa, and the number of clones was quantified. The
percentage of cells displaying membrane alterations
("blebs”) after transduction with retroviral vectors was
detected and quantified by counting at least 3 randomly
selected areas with at least 200 EGFP-positive cells
using a Zeiss Axiovert 135 fluorescence microscope
(Zeiss AG, Jena, Germany) at 400× magnification. All
experiments were performed in triplicates and repeated
at least for 2 times with similar results. Statistical analy-
sis was performed with student’s T test.
SOX2-shRNA retroviral vectors and transduction
For the transduction of DNA-sequences encoding
shRNA-molecules we used the self inactivating retroviral
Moloney murine leukemia virus backbone pRVH-1. This
vector contains a H1 polymerase III promoter for the
expression of shRNA molecules in reverse orientation.
pRVH1 was digested with EcoRI and NotI and ligated
with an CMV immediate early promoter and EGFP con-
taining appropriate restriction sites, resulting in the vec-
tor pRVH-N1-EGFP. 9 different SOX2 target sequences
were identified using an algorithm provided by Ambion
Inc. http://www.ambion.com, synthesized (Eurofins
MWG Biotech, Ebersberg, Germany) and after annealing
of the upper and bottom strands were ligated into the
BglII/SalI-restrictions sites of pRVH-N1-EGFP. After
testing, the following most effective shSOX2 hairpin
sequences were used in our experiments: 788 upper: 5’-
gatccccGAAGGATAAGTACACGCTGTTCAAGAGA-
CAGCGTGTACTTATCCTTCTTTTTTggc-3’, 788 bot-
tom: 5’-tcgagccAAAAAAGAAGGATAAGTACACGC
TG TCTCTTGAACAGCGTGTACTTATCCTTCggg-3’,
2378 upper: 5’-gatccccCTGC CGAGAATCCATGTA
TATCTCGAGATATACATGGATTCTCGGCAGTT
TTTggc-3’, 2378 bottom: 5’-tcgagccAAAAACTGCCGA
GAATCCATGTATATCTCGA GATATACATGGATTC
TCGGCAGggg-3’. As control we included a previously
described RNA hairpin against luciferase [55]. Retroviral
particles were generated as described previously [56].
Briefly, 293T cells were cotransfected with an expression
construct for gag-pol (pHIT60), the MoMuLV-based
retroviral vectors and the vesicular stomatitis virus G-
protein (pMD.G2). Viral supernatants were harvested 48
and 72 h after transfection. 10
5 target cells were plated
in 30 mm dishes a day before transduction and were
transduced with retroviral supernatants at a multiplicity
of infection (MOI) of 20. Transduction experiments
were freshly performed for each single experiment in
triplicates for shSOX2 and shLuc vectors and used for
the analyses. Transduction efficiencies usually were in
the range of 95%-99%. If not otherwise indicated, the
transduced cells were cultivated for five days in BME
medium with supplements and then were used for the
experiments.
Life cell imaging
Cells were cultured and imaged in 2-well chamberslides
( N a l g eN u n c ,R o c h e s t e r ,U S A )u s i n ga ni n v e r s eA F
6000LX microscope (Leica, Wetzlar, Germany) with a
humidified chamber at 37°C and 5% CO2.F i v ed a y s
after transduction with retroviral vectors encoding
shSOX2 #2378 and shLuc, respectively, pictures of cells
were taken every 5 or 10 minutes. For ROCK inhibition
experiments 16 μlo fa1 0μM Y27632 solution in
H2Odd were added to the cells per ml culture medium.
The experiments were repeated four times with similar
results.
Phalloidin-TRITC staining and indirect
immunofluorescence analysis
Transduced cells on poly-L-Lysine mounted glass slides
were fixated for 20 min with 4% paraformaldhyde (PFA)
in PBS. Fixated cells were treated with ice cold permea-
bilization solution (0.1% sodium citrate in PBS, 0.1%
Triton X-100) for 5 min. Filamentous actin was stained
with phalloidin-TRITC (8 μM) (Sigma) for 1 h. Confocal
laser scan analysis was performed using Leica SP5
i n v e r s em i c r o s c o p e( W e t z l a r ,G e r m a n y ) .T h i c k n e s so f
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and with affected morphology was compared to shLuc
control cells using the Leica Application Suite Software
2.2.0. For indirect immunofluorescence analyses follow-
ing primary antibodies were used: Anti-h-CD44 (mouse
monoclonal; 1:100; BD Biosc.), anti-h-ezrin (mouse
monoclonal; 1:100; BD Biosciences, Franklin Lakes,
USA), anti-h-OCT4 (rabbit polyclonal; 1:100; Abcam,
Cambridge, USA), anti-h-SOX2 (goat polyclonal; 1:100;
R & DS y s t e m s ,M i n n e a p o l i s , USA). Cells were washed 3
times with PBS + 0.1% BSA and subsequently incubated
with species specific secondary antibodies (Cy3 conju-
gated; 1:100; Jackson IR, West Grove, PA) for 1 hour.
For colocalization studies of CD44 and Ezrin we used
non-fixed transduced cells which were stained using
anti-h-ezrin and secondary FITC-conjugated secondary
antibody followed by staining with PE-labeled anti CD44
(mouse monoclonal, 1:100, BD Biosciences). Finally,
cells were washed three times in PBS/0.1% BSA and
once in double distilled water, before being examined by
confocal laser scanning microscopy (Leica SP5 inverse
MP).
Western blot analysis
Total cell lysates were prepared using 2× Laemmli-pro-
tein-sample-buffer (Sigma). Samples were subsequently
cooked for 5 min and placed in an ultrasonic bath for
15 min. Equal amounts of proteins was separated in
SDS-polyacrylamide gels and blotted onto PVDF mem-
branes. After blocking the membranes were incubated
with the following primary antibodies for 1 hour: anti-
cyclinD1 (rabbit polyclonal; 1:500; Santa Cruz Biotech,
Heidelberg, Germany), anti-cyclinE (rabbit polyclonal;
1:500; Santa Cruz), anti-h-FAK (mouse monoclonal;
1:1000; BD Biosciences), anti-h-FAK(pY397) (mouse
m o n o c l o n a l ;1 : 1 0 0 0 ;B DB i o s c i e n c e s ) ,a n t i - h - G F A P
(mouse monoclonal; 1:1000; Chemicon, Chandlers Ford,
UK), anti-h-NEDD9/HEF1 (mouse monoclonal; 1:1000;
Abcam), anti-h-MMP1 (mouse monoclonal; 1 μg/ml;
R&D Systems), anti-h-MMP2 (mouse monoclonal; 1 μg/
ml; R&D Systems), anti-h-p21 (mouse monoclonal; 2
μg/ml; R&D Systems), anti-h-RB (mouse monoclonal;
1:750; Abcam), anti-h-phosphoRB (mouse monoclonal;
0.75 μg/ml; Sigma), anti-h-SOX2 (goat polyclonal;
1:1000; R&D Systems), anti-b-Catenin (mouse monoclo-
nal, BD Biosciences; 1:1000), anti-ROCK1 (mouse
monoclonal, Santa Cruz; 1:1000), anti-ROCK2 (rabbit
p o l y c l o n a l ,S a n t aC r u z ;1 : 5 0 0 ) ,a n t ip h o s p h o - S e r i n e 1 9
myosin light chain (MLC-P) (mouse monoclonal, Cell
Signaling Technologies, Danvers, USA, 1:500) anti-h-
aTubulin (mouse monoclonal; 1:1000; Sigma). Induction
of apoptosis was analyzed by using an anti Caspase 3
antibody (mouse monoclonal; 1:1000; Cell Signaling
Technology). After incubation with the primary antibody
the membranes were washed three times with TBS-TT
and once 10 min with TBS-buffer. Subsequently the
membranes were incubated for 1 hour with appropriate
species specific secondary antibodies conjugated with
HRP (1:1000; Dako, Glostrup, Denmark). After washing
the blots were imaged using ECL-detection solution (GE
Healthcare, Freiburg, Germany) and a LAS3000 device.
RhoA activation assay
RhoA-GTP was measured using a RhoA-G-LISA™
(Cytoskeleton Inc., Denver, USA) according to the
instructions of the provider. As a negative control frac-
tion wild type cells were starved in serum free medium
to completely deactivate RhoA [57]. As positive control
for fully activated RhoA signaling type cells were treated
with lysophosphatic acid (LPA), a common RhoA activa-
tor [58]. Probes were measured in a Tecan ELISA reader
at 490 nm. shLuc-transduced cells were compared to
cells transduced with SOX2 #sh788 and SOX2 #sh2378,
respectively. The experiment was performed in tripli-
cates and repeated twice with similar results. Statistical
analysis was performed with student’s T test.
Flow cytometry for cell cycle analysis and apoptosis
Analysis of the cell cycle and apoptosis was determined
by flow cytometry of propidium iodide-stained cells
using Cell Quest Software (BD, Heidelberg, Germany).
Briefly, adherent cells and cells in the cell culture super-
natant were collected, washed in PBS and fixed in 70%
(v/v) ethanol. After centrifugation of the cells at 600 g
at 20°C for 10 min the cell pellet was suspended in 0.5
ml DNA-extraction buffer (4 mM citric acid in 0.2 M
Na2HPO4; pH 7.8). After 5 min incubation at room
temperature the cells were spun down at 600 g. The
cells were then washed once with PBS, followed by incu-
bation in PBS containing 40 μg/ml propidium iodide
(Sigma, Taufkirchen, Germany) and 200 μg/ml RNase A
(Sigma, Dreieich, Germany) for 1 h at room temperature
in the dark. Stained nuclei were then analyzed using a
Becton Dickinson FACScan (BD) with at least 10,000
events/determination. The experiments were performed
in triplicates and repeated at least twice. Statistical ana-
lysis was performed with student’s T test.
Migration and invasion assays
The invasion activity of SOX2-depleted cells was mea-
sured by Boyden-chamber assay using BD BioCoat
Matrigel Invasion Chambers™ (BD Biosciences) which
consists of a membrane with 8 μm pores and a base-
ment matrix, as recommended by the supplier. 10,000
cells were serum-starved for 24 h and plated with
serum-free BME medium in the insert chambers. The
lower chambers were filled with DMEM with 10% FCS.
After 24 h incubation the degraded matrigel was
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cells were removed. The EGFP-positive cells that had
invaded through the Matrigel and pores to the other
side of the membrane were fixed using 4% paraformal-
dehyde, and counted using a Zeiss Axiovert 135 fluores-
cence microscope. To determine the invasion index we
employed uncoated Boyden-chambers (BD BioCoat
Companion plates (BD Biosciences)) having 8 μm pores.
The calculation of the invasion index was made by the
formula cell number of invading cells through matrix/
cell number of cells on control filter (BD Companion
plate). Due to the lack of adherence to the filter, cells
having an amoeboid-like phenotype could be measured
in the lower chambers of Companion plates. The calcu-
lation of the amoeboid migration index was made by
the formula cell number in the lower well/cell number
on control filter. All migration experiments were per-
formed in triplicates and repeated twice. Statistical ana-
lysis was performed with student’s T test. For the brain
tissue invasion assay freshly prepared roughly 8 mm
3
cubes of mouse brains were incubated for 5 hours in
BME medium with 10% FCS in a 48 well plate. There-
after the brain pieces were transferred into clean wells
and washed with sterile PBS and transferred into wells
containing suspensions of 10,000 serum-starved SOX2-
depleted cells and control cells, respectively, in serum
free BME medium. After 36 h the brain cubes were
transferred into clean wells, washed and covered with
serum free BME medium. Subsequently the samples
were analyzed and imaged using a Zeiss Axiovert 135
fluorescence microscope. The experiments were
repeated twice with similar results.
TCF/LEF-luciferase reporter gene assay
U343-MG and U373-MG glioma cells were transduced
with lentiviral particles of Lenti TCF/LEF luciferase
reporter at a MOI of 25 (SABiosciences/BIOMOL
GmbH, Hamburg, Germany). After selection with puro-
mycin the cells were transduced with retroviral pRVH1-
sh2378-EGFP and empty vector, respectively. 5 days
after transduction the activity of the TCF/LEF-element
was measured with 50,000 cells/well in triplicates using
the Luciferase Assay System (Promega, Mannheim, Ger-
many) and an Orion Microplate Luminometer (Berthold
Technologies, Bad Wildbad, Germany). The luciferase
mediated light emission was normalized to the expres-
sion level of the co-transduced reporter EGFP as deter-
mined in Western blot analysis. The experiments were
performed in quadruplicates and at least repeated twice.
Statistical analysis was performed with student’s T test.
Mouse xenograft assays
9w e e k so l dN M R I
nu/nu mice were obtained from the
a n i m a lf a c i l i t yo ft h eU n i v e r s i t yo fD r e s d e n .M i c ew e r e
held under standardized pathogen-free conditions with
ad libitum access to food and water. Experiments were
approved by the responsible local authorities according
to the German Animal Protection Law. 5 × 10
5 U343-
MG cells resuspended in 10 μlP B Sw e r eu s e df o r
stereotactical injections in the right brain hemisphere.
In total, survival of 26 mice transplanted with U343-MG
cells with knockdown of SOX2 and survival of 26 mice
transplanted with shLuc-transduced control cells was
investigated in two independent experiments. Mice were
killed when neurological symptoms became apparent. 12
brains transplanted with U343-MG cells with knock-
down of SOX2 and 9 brains transplanted with shLuc-
transduced U343-MG cells were randomly selected and
were subjected to standard histology. Whole brains of
mice were fixed in buffered 4% formalin (pH 7), cut into
3-4 frontal slices per brain, dehydrated and embedded in
Paraffin. 5 μm thick serial sections were cut and stained
with hematoxylin and eosin (H&E) and then evaluated
using a Zeiss Axioplan 2 microscope. A semi-quantita-
tive scoring system using scores from 1-4 was used to
calculate the size of the tumors and specific traits such
as necrosis, endothelial proliferation, spreading along
perivascular spaces or diffu s es i n g l ec e l ls p r e a d i n g
according to a scoring system described previously [59].
Briefly, score values were as follows: Tumor size: Score
1 = visible on surface and < 0.1 cm in diameter, Score 2
= up to 5-10% total volume of brain and 0.1-0.2 cm in
diameter, Score 3 = up to 10-30% total volume of brain
a n d>0 . 2c mi nd i a m e t e r ,S c o r e4=m o r et h a n5 0 %o f
total volume of brain and > 1 cm in diameter; Necrosis:
Score 1 = necrotic area < 0.1 cm in diameter, Score 2 =
necrotic area up to 0.2 cm in diameter, Score 3 = necro-
tic areas > 0.2 cm or with multiple smaller areas; Vascu-
lar proliferation: Score 1 = suspicious endothelium or
single vascular proliferation, Score 2 = glomeruloid vas-
cular proliferation; Infiltration following vessels: Score 1
= tumor cells infiltration following up to two vessels,
Score 2 = infiltration following three to seven vessels,
Score 3 = Infiltrations following more than seven ves-
sels; Diffuse infiltration: Score 1 = few suspicious cells,
S c o r e2=s t r o n g l yi n c r e a s e dc e l l u l a r i t y( u pt o5 0 %
increase), Score 3 = more than 50% increase in cellular-
ity. Student’s t-test and LogRank test were used for sta-
tistical analysis
Additional material
Additional file 1: This figure shows transduction efficiencies of
retroviral shRNA-vectors and clonogenic long term survival of
U343-MG and U373-MG cells with knock down of SOX2. a:
Representative FACS analysis showing EGFP marker gene expression of
U343-MG and U373-MG glioma cells two days after transduction with
the depicted retroviral vectors. Open histograms represent non
transduced cells, black histograms depict transduced cells expressing
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Page 14 of 16EGFP. b: Clonogenic survival of U343-MG and U373-MG cells transduced
with shSOX2 #2378 and shLuc control, respectively. The number of
surviving clones was quantified. *p < 0.05 when U343-MG cells with
knockdown of SOX2 were compared to the shLuc controls.
Additional file 2: Time lapse video imaging showing the
development of membrane protrusion s in U343-MG cells with
knockdown of SOX2. This video file shows the development of
membrane protrusions and amoeboid-like movements in U343-MG
glioma cells after knockdown of SOX2. The file can be viewed using
Windows Media Player or other standard media players.
Additional file 3: Time lapse video imaging showing blebbing and
movement of U343-MG cells with knockdown of SOX2. This video
file shows a single U343-MG glioma cells after knockdown of SOX2 and
the transition from blebbing to an amoeboid-like movement. In
particular the development of a single protrusion in the direction of
movement can be seen. The file can be viewed using Windows Media
Player or other standard media players.
Additional file 4: Time lapse video imaging showing cell motility of
U343-MG cells with knockdown of SOX2. This video file shows the
motility of a single U343-MG glioma cells after knockdown of SOX2. The
file can be viewed using Windows Media Player or other standard media
players.
Additional file 5: This figure shows expression of CD44s in U343-
MG and U373-MG cells and its colocalization with ezrin in single
membrane protrusions of cells with amoeboid appearance. a:
Western Blot showing expression of the standard isoform of CD44
(CD44s) in U343-MG and U373-MG glioma cells. b: Confocal laser scan
microscopy showing the colocalization of CD44 and ezrin at membranes
of shLuc-transduced cells and in single membrane protrusion in cells
with knock down of SOX2 (arrowheads). Bars represent 10 mm.
Additional file 6: Time lapse video imaging showing that ROCK-
inhibitor Y27632 blocks blebbing and membrane protrusions in
U343-MG cells with knockdown of SOX2. This video file shows U343-
MG glioma cells after knockdown of SOX2 and ongoing membrane
protrusions and retractions. After adding the ROCK inhibitor Y27632 the
formation of the membrane protrusions (blebs) is blocked. The file can
be viewed using Windows Media Player or other standard media players.
Additional file 7: This figure shows images of migrating U373-MG
cells with knock down of SOX2 and of controls in organotypic brain
tissue. Brain tissue invasion assay showing infiltration of a: starved U343-
MG and c: starved U373-MG cells transduced with shSOX2 #2378 and of
b: starved shLuc-transduced U343-MG and of starved shLuc-transduced
U373-MG control cells into murine brain tissue soaked with BME medium
containing 10% fetal calf serum. a: Note the appearance of U343-MG
and in b: U373-MG cells with knockdown of SOX2 and membrane
protrusions. Cell displaying membrane protrusions are enlarged. U343-
MG and U373-MG shLuc control cells normally displayed an elongated
spindle-like morphology (see close up). Arrows depict the border of the
brain tissues.
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